Reimbursement

Reimbursement in the context of medical devices refers to the process by which healthcare providers or suppliers receive payment for the cost of medical devices and associated services from public or private payers. Unlike regulatory approval or CE marking, reimbursement is not a determination of safety and effectiveness but a financial and health economics decision: whether a device is considered medically necessary and eligible for coverage under a given health system.

Key Jurisdictional Differences

• United States (FDA / CMS): FDA approval or clearance (e.g., 510(k), PMA, De Novo) is a prerequisite, but does not guarantee reimbursement. Coverage is determined by the Centers for Medicare & Medicaid Services (CMS) under Social Security Act §1862(a)(1)(A), requiring items to be “reasonable and necessary.” Commercial insurers may impose additional technology assessments and coding requirements (HCPCS, CPT).
• European Union (MDR/IVDR): CE marking under MDR/IVDR is required to place a device on the market, but reimbursement decisions are made at the Member State level. Many states require evaluation by a national Health Technology Assessment (HTA) body (e.g., HAS in France, G-BA in Germany, NICE in the UK though no longer EU).
• Canada: Health Canada licensing (Medical Devices Regulations, SOR/98-282) is required for market access; however, provincial payers determine reimbursement coverage, often with HTA input from CADTH.
• Japan (PMDA/MHLW): After regulatory approval, reimbursement requires listing in the National Health Insurance (NHI) price listing, subject to PMDA and MHLW evaluation.
• Australia (TGA): Inclusion in the Australian Register of Therapeutic Goods (ARTG) is required for market entry; reimbursement decisions are handled separately under the Prostheses List or Medicare Benefits Schedule (MBS).

Typical Reimbursement Process

• Regulatory approval or certification: FDA clearance/approval, CE marking, or equivalent.
• Coverage determination: Payer (e.g., CMS, private insurer, HTA body) decides if the device is medically necessary and falls within a covered benefit category.
• Coding: Assignment of a reimbursement code (HCPCS, CPT, DRG, or national tariff codes).
• Payment determination: Payers establish reimbursement levels (fixed fee, bundled, cost-plus, or negotiated).
• Post-market evidence: Some payers require real-world evidence or outcomes studies for continued coverage (“coverage with evidence development”).

Important Considerations

• Regulatory ≠ Reimbursement: Market authorization (FDA, CE mark, etc.) does not itself establish coverage or payment.
• Timing: Manufacturers often plan regulatory and reimbursement strategies in parallel, as HTA bodies may request data beyond regulatory submissions.
• Global complexity: Each jurisdiction has unique processes, and multi-market launches require country-specific reimbursement planning.
• Clinical and economic evidence: Beyond safety and performance, payers often require demonstration of cost-effectiveness, improved outcomes, or quality-of-life benefits.

Quick FAQ